ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Serial plasma cell-free circulating tumor DNA tests identify genomic alterations for early prediction of osimertinib treatment outcome in EGFR T790M-positive non-small cell lung cancer

Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Ching-Yao Yang; Tzu-Hsiu Tsai; Wei-Yu Liao; Chao-Chi Ho; Chia-Chi Lin; Jin-Yuan Shih; Chong-Jen Yu; Ross A. Soo; James Chih-Hsin Yang
JTO Clinical and Research Reports2020-9-19DOI: 10.1016/j.jtocrr.2020.100099
7阅读
引用收藏
分享

摘要

Introduction<br/>Recent advances in the detection of genomic DNA from plasma samples allow us to follow tumor DNA shedding in plasma during systemic treatment. Osimertinib is the standard-of-care for NSCLC patients with acquired EGFR T790M mutations. We assessed changes in serial plasma cell-free circulating tumor DNA (ctDNA) genomic alterations to predict osimertinib efficacy.<br/>Methods<br/>We prospectively collected plasma from patients having EGFR-mutated advanced NSCLC previously treated with EGFR-tyrosine kinase inhibitor therapy and with acquired EGFR T790M mutation detected by standard methods. Plasma samples were collected before starting osimertinib treatment, 4 weeks following osimertinib treatment and upon progression. CtDNA was analyzed utilizing the Guardant360 assay.<br/>Results<br/>Fifteen eligible patients received osimertinib. Before starting treatment, EGFR-activating mutations were detected in the ctDNA of all patients, and EGFR T790M was detected in 93% of the cases. Osimertinib treatment was associated with an objective response rate of 53% and a median progression-free survival of 7.3 months. Twelve of the 15 patients had undetectable plasma T790M and decreased activating mutation allelic frequency (AF) at week 4. None of the 12 patients had disease progression within 16 weeks. For the remaining 3 patients, with detectable plasma T790M (n = 2) or increased activating mutation AF (n = 1) at week 4, two had progressive disease within 16 weeks (p = 0.03).<br/>Conclusions<br/>In patients with EGFR-mutated advanced NSCLC, persistent EGFR T790M or increasing activating mutations AF as detected in ctDNA four weeks after the start of osimertinib treatment may predict disease progression within 16 weeks.

学科与关键词

关键词
Non-small cell lung cancerEGFR mutationsctDNAosimertiniboutcome prediction
相关
加载中…
  • Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC.
    Buder Anna; Hochmair Maximilian J; Schwab Sophia; Bundalo Tatjana; Schenk Peter; Errhalt Peter; Mikes Romana E; Absenger Gudrun; Patocka Kurt; Baumgartner Bernhard; Setinek Ulrike; Burghuber Otto C; Prosch Helmut; Pirker Robert; Filipits Martin*Journal of Thoracic Oncology, 2018.
  • Circulating tumor DNA analysis of EGFR -mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment
    Jamie J. Beagan; Sander Bach; Robert A. van Boerdonk; Erik van Dijk; Erik Thunnissen; Daan van den Broek; Janneke Weiss; Geert Kazemier; D Michiel Pegtel; Idris Bahce; Bauke Ylstra; Daniëlle A.M. HeidemanLung Cancer, 2020, 145: 173-180.被引 6
  • Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients
    Eva Boysen Fynboe Ebert; Tine McCulloch; Karin Holmskov Hansen; Hanne Linnet; Boe Sorensen; Peter Meldgaard2020.
查看全部 →

发表信息

论文状态
公开发表
期刊
JTO Clinical and Research Reports
发表日期
2020-09-19
页码
100099
DOI
10.1016/j.jtocrr.2020.100099
成果收录
SCIENCEDIRECT

作者

  • B

    Bin-Chi Liao (第一作者)

  • W

    Wei-Hsun Hsu

查看全部 12 位作者收起作者
  • J

    Jih-Hsiang Lee

  • C

    Ching-Yao Yang

  • T

    Tzu-Hsiu Tsai

  • W

    Wei-Yu Liao

  • C

    Chao-Chi Ho

  • C

    Chia-Chi Lin

  • J

    Jin-Yuan Shih

  • C

    Chong-Jen Yu

  • R

    Ross A. Soo

  • J

    James Chih-Hsin Yang

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417